Public impact, prevention, and treatment of cataracts by Frances Wu et al.
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2015. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: Lingzhao1976@126.com) 
• INSIGHT • November 2015  Vol.58  No.11: 1157–1159 
 doi: 10.1007/s11427-015-4939-8 
Public impact, prevention, and treatment of cataracts 
WU Frances1, WANG Sha1, ZHU Jie1, RUTGARD Jeff1, YAN Yong-Bin2, ZHANG Kang1 & 
ZHAO Ling3,4* 
1Shiley Eye Institute, Department of Ophthalmology and Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
92093, USA; 
2State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China; 
3State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China; 
4Institute of Molecular Medicine, Peking University, Beijing 100871, China 
Received September 11, 2015; accepted September 17, 2015; published online September 30, 2015 
 
Citation:  Wu F, Wang S, Zhu J, Rutgard J, Yan YB, Zhang K, Zhao L. Public impact, prevention, and treatment of cataracts. Sci China Life Sci, 2015, 58: 




The human lens is composed anteriorly of a single layer of 
epithelial cells, which undergo mitosis and migrate to the 
lens equator where they differentiate into lens fiber cells [1]. 
The elongated lens fiber cells express high levels of soluble 
crystallin proteins that do not undergo turnover and must 
remain relatively stable over a lifetime. The three-     
dimensional organization of crystallins is crucial for lens 
transparency and refractive power and therefore visual acu-
ity. The crystallins have some of the highest protein con-
centrations in the human body and are comprised of two 
families, the α-crystallins and βγ-crystallins. α-crystallin 
acts as a chaperone that sequesters misfolded proteins and 
prevents widespread protein aggregation. In cataract, the 
formation of insoluble protein aggregates is believed to 
overwhelm the native chaperone system [1] (Figure 1). The 
aggregates scatter light and cause lens opacification, leading 
to decreased visual acuity and eventually blindness if left 
untreated. 
Cataracts are the leading cause of blindness worldwide 
and the leading cause of visual impairment in the United 
States [2]. Annually, millions of people will require surgical 
treatment for cataract, and this number is only expected to 
increase as the population ages. The economic, as well as 
human, costs of the disease are massive. The burden is 
greatest in the developing world, where most people do not 
have access to surgical care. In many developing countries, 
the incidence of new cataract exceeds the rate of growth of 
surgical services, leading to a backlog of patients who are in 
need of treatment [3]. 
Genetic causes of cataract are relatively uncommon and 
tend to manifest as early onset disease. Congenital cataract 
is often associated with mutations in crystallin genes. Muta-
tions have also been identified in genes encoding other lens 
proteins, including membrane proteins, transcription factors, 
cytoskeletal proteins, and growth factors [4]. Age-related 
cataract is extremely common in people older than 50 years 
of age and accounts for the vast majority of this disease. 
The pathogenesis is thought to be multifactorial, with pro-
teomic analyses demonstrating covalent modifications to 
wild-type lens proteins in many cases [1]. Molecular and 
epidemiologic studies have elucidated some of the factors 
that contribute to the development of age-related cataract. 
Ultraviolet (UV) radiation and oxidative stress are thought 
to play particularly important roles. UV radiation from sun-
light causes the formation of reactive oxygen species. High 
levels of glutathione in the lens normally protect lens pro-
teins from oxidation, but they diminish with age, resulting 
in oxidative damage that in turn drives protein misfolding 
and aggregation in the development of cataract. In addition, 
cataract is also a relatively early complication of uncon-
trolled diabetes. High glucose levels lead to protein gly-
cation, which interferes with the chaperone function of 
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Figure 1  Proposed scheme illustrating a process by which crystallin proteins undergo misfolding and form aggregates, and a potential strategy for revers-
ing aggregation and increasing solubility (modified from reference [1]). 
α-crystallins and again causes protein misfolding. Other risk 
factors identified for cataract include cigarette smoking, 
high alcohol intake, medications, and trauma [2]. 
The current standard-of-care for visually significant cat-
aracts is surgical management. Cataract extraction with 
phacoemulsification and intraocular lens (IOL) implantation 
is the preferred technique. Although this procedure is very 
effective with a high rate of success, it can be associated 
with complications such as posterior capsule opacification 
and necessitating additional procedures to achieve desired 
visual acuity. In addition, it requires the use of specialized 
equipment for phacoemulsification. More recently, manual 
small incision cataract surgery (MSICS) with posterior 
chamber IOL implantation has been favored in developing 
countries, as this procedure is relatively rapid and inexpen-
sive [3]. However, access to care in these regions remains 
limited by cost as well as a lack of facilities and physicians. 
Given the limitations posed by the current surgical 
treatment for cataract in patients in both developed and de-
veloping nations, the concept of non-surgical therapy is 
intriguing. Strategies for cataract prevention using pharma-
cological therapies have been investigated, but at present 
there is no FDA-approved treatment. In particular, the role 
of oxidative damage in the pathogenesis of cataract has 
fueled interest in antioxidant drugs as a possible therapeutic 
strategy [5,6]. Synthetic small molecule compounds have 
been shown to protect lens epithelial cells from oxidative 
stress in vitro. However, the in vivo delivery of antioxidant 
drugs to the lens presents several challenges; most im-
portantly, the utility of antioxidants has been hindered by 
low absorption of topical formulations into the lens nucleus. 
These antioxidant molecules tend to be either hydrophilic or 
lipophilic, preventing them from bypassing the lipophilic 
corneal epithelium or making them poorly water soluble, 
respectively. Other approaches involving aspirin and aspi-
rin-like drugs and protein stabilizers have also been inves-
tigated, but have so far been limited due to undesirable side 
effects. 
A recent study published by Zhao et al. [7] demonstrated 
that lanosterol is a key molecule in the proper folding of 
lens proteins. Mutations in lanosterol synthase (LSS), an 
enzyme in the cholesterol synthesis pathway, were identi-
fied in two consanguineous families with congenital cata-
ract. Furthermore, lanosterol had the ability to reduce cata-
racts in rabbit lenses and in dogs in vivo. Lanosterol is an 
amphipathic molecule that is hypothesized to intercalate 
into core hydrophobic areas of protein aggregates and in-
crease their solubility (Figure 1). Topical administration of 
lanosterol has the advantage of providing a convenient, 
non-surgical method for prevention and/or treatment of cat-
aracts. It may be useful in patients with early cataract that is 
not severe enough to warrant surgical intervention, delaying 
or eliminating the need for surgery in the future. In addition, 
lanosterol could have utility in treating patients who have 
contraindications to surgical management of cataract. The 
impact on the developing world is potentially great, as mil-
lions of people with cataract do not have access to surgical 
care. Blindness and visual impairment contribute to de-
creased quality of life, accidents, and negative economic 
consequences stemming from reduced productivity.  
The adverse effects of lanosterol treatment will need to 
be characterized; however, since lanosterol is an endoge-
nous protein, it is expected to have a favorable safety pro-
file. Topical administration should minimize systemic ef-
fects while ensuring adequate delivery of drug into the lens 
material. Because lanosterol is an amphipathic molecule, a 
topical formulation may have improved bioavailability into 
the lens nucleus compared to hydrophilic or lipophilic 
compounds. Nevertheless, there are a number of possible 
limitations. Lanosterol eye drops may not penetrate dense 
cataracts, especially those of the nuclear sclerotic subtype. 
This is because of tight packing of intracellular protein ag-
gregates. Lanosterol may not be effective for hereditary 
forms of cataract if the three-dimensional structure of lens 
proteins is highly disrupted, as with cases involving crystal-
lin gene mutations. In addition, cataracts treated with lanos-
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terol are highly likely to recur because the underlying path-
ogenesis of protein denaturation remains unchanged.  
Future directions include determining the specific phar-
macokinetics and pharmacodynamics of lanosterol in hu-
man lenses, with the goal of formulating an eye drop for 
eventual treatment of patients with cataracts. Initiation of 
clinical trials should be feasible within the next few years. 
Furthermore, lanosterol represents an appealing paradigm 
for the treatment of cataract and other protein aggregation 
diseases. These findings support the idea that small mole-
cules may be used to facilitate proper protein folding and 
prevent or reverse aggregation in neurodegenerative diseas-
es, which collectively account for a significant cause of 
mobidity and mortality.  
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